Companies › Amneal Pharmaceuticals
1 active drug program in 17 registered trials: 10 Phase 2, 4 Phase 4, 2 Phase 1, 1 Phase 3; Neurology, Genitourinary, Metabolic and endocrine, Oncology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Testosterone Cypionate Androgen Receptor agonist | AR | Phase 3 | Male Hypogonadism; Weaning Failure; Transgenderism; Localized Prostate Carcinoma … | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06592144 | Testosterone Cypionate | Phase 4 | Weaning Failure | Neurology | Aug 2026 |
| NCT06111209 | Testosterone Cypionate | Phase 2 | Stress Urinary Incontinence | Genitourinary | Dec 2026 |
| NCT04731376 | Testosterone Cypionate | Phase 1 | Hypogonadism | Oncology | Dec 2026 |
| NCT06059118 | Testosterone Cypionate | Phase 2 | Prostate Cancer | Oncology | Jan 2027 |
| NCT07898072 | Testosterone Cypionate | Phase 3 | Male Hypogonadism | Metabolic and endocrine | Mar 2027 |
| NCT04363164 | Testosterone Cypionate | Phase 2 | Castration Resistant Metastatic Prostate Cancer | Oncology | Jul 2027 |
| NCT06392295 | Testosterone Cypionate | Phase 2 | Prostate Cancer | Oncology | Aug 2027 |
| NCT06392295 | Testosterone Cypionate | Phase 2 | Prostate Cancer | Oncology | Aug 2027 |
| NCT07476001 | Testosterone Cypionate | Phase 2 | Metastatic Castration-resistant Prostate Cancer | Oncology | Sep 2027 |
| NCT04798469 | Testosterone Cypionate | Phase 2 | Opioid Use | Psychiatry | Sep 2027 |
| NCT06100705 | Testosterone Cypionate | Phase 2 | Metastatic Castration-resistant Prostate Cancer | Oncology | Dec 2027 |
| NCT04704505 | Testosterone Cypionate | Phase 2 | Prostate Adenocarcinoma | Oncology | Feb 2028 |
| NCT06305598 | Testosterone Cypionate | Phase 1 | Castration-Resistant Prostate Carcinoma | Oncology | Mar 2028 |
| NCT07092527 | Testosterone Cypionate | Phase 4 | Transgenderism | Psychiatry | Nov 2028 |
| NCT06733350 | Testosterone Cypionate | Phase 4 | Localized Prostate Carcinoma | Oncology | Jan 2029 |
| NCT07142551 | Testosterone Cypionate | Phase 2 | Metastatic Castration-resistant Prostate Cancer | Oncology | Jun 2030 |
| NCT07278362 | Testosterone Cypionate | Phase 4 | Prostate Cancer | Oncology | May 2031 |
Cash of $157m on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Aragon Pharmaceuticals Tolmar Halozyme Therapeutics Lipocine Upsher-Smith Laboratories
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.